259 related articles for article (PubMed ID: 33457098)
41. Immunology and immunotherapy of neuroblastoma.
Seeger RC
Semin Cancer Biol; 2011 Oct; 21(4):229-37. PubMed ID: 21971567
[TBL] [Abstract][Full Text] [Related]
42. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins.
Cheresh DA; Pierschbacher MD; Herzig MA; Mujoo K
J Cell Biol; 1986 Mar; 102(3):688-96. PubMed ID: 3005335
[TBL] [Abstract][Full Text] [Related]
43. Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2.
Müller J; Reichel R; Vogt S; Müller SP; Sauerwein W; Brandau W; Eggert A; Schramm A
PLoS One; 2016; 11(10):e0163648. PubMed ID: 27716771
[TBL] [Abstract][Full Text] [Related]
44. Distribution of disialoganglioside GD2-antigen and binding of anti-GD2 antibodies on spheroids of neuroblastoma cell line.
Heiss P; Bermatz S; Wehnes H; Heinzmann U; Senekowitsch-Schmidtke R
Anticancer Res; 1997; 17(4B):3145-7. PubMed ID: 9329622
[TBL] [Abstract][Full Text] [Related]
45. The glycosphingolipid GD2 as an effective but enigmatic target of passive immunotherapy in children with aggressive neuroblastoma (HR-NBL).
Rovigatti U
Cancer Lett; 2021 Apr; 503():220-230. PubMed ID: 33271265
[TBL] [Abstract][Full Text] [Related]
46. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.
Siebert N; Seidel D; Eger C; Brackrock D; Reker D; Schmidt M; Lode HN
J Immunol Methods; 2013 Dec; 398-399():51-9. PubMed ID: 24055592
[TBL] [Abstract][Full Text] [Related]
47. Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma.
Raffaghello L; Pagnan G; Pastorino F; Cosimo E; Brignole C; Marimpietri D; Bogenmann E; Ponzoni M; Montaldo PG
Cancer Lett; 2003 Jul; 197(1-2):151-5. PubMed ID: 12880975
[TBL] [Abstract][Full Text] [Related]
48. Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma.
Chan GC; Chan CM
Biomolecules; 2022 Feb; 12(3):. PubMed ID: 35327550
[TBL] [Abstract][Full Text] [Related]
49. Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy.
Liu X; Wills CA; Chen L; Zhang J; Zhao Y; Zhou M; Sundstrom JM; Schell T; Spiegelman VS; Young MM; Wang HG
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35483745
[TBL] [Abstract][Full Text] [Related]
50. Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice.
Zobel MJ; Zamora AK; Wu HW; Sun J; Lascano D; Malvar J; Wang L; Sheard MA; Seeger RC; Kim ES
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428582
[TBL] [Abstract][Full Text] [Related]
51. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Clin Cancer Res; 1998 Sep; 4(9):2135-9. PubMed ID: 9748131
[TBL] [Abstract][Full Text] [Related]
52. Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell.
Saito M; Yu RK; Cheung NK
Biochem Biophys Res Commun; 1985 Feb; 127(1):1-7. PubMed ID: 2579648
[TBL] [Abstract][Full Text] [Related]
53. A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [
Trautwein NF; Schwenck J; Seitz C; Seith F; Calderón E; von Beschwitz S; Singer S; Reischl G; Handgretinger R; Schäfer J; Lang P; Pichler BJ; Schulte JH; la Fougère C; Dittmann H
Theranostics; 2024; 14(3):1212-1223. PubMed ID: 38323317
[No Abstract] [Full Text] [Related]
54. Apoptosis is responsible for the cytotoxic effects of anti-GD2 ganglioside antibodies and aurora A kinase inhibitors on human neuroblastoma cells.
Durbas M; Rokita H; Horwacik I; Wiśniewska A; Nowak I
Acta Biochim Pol; 2022 Jul; 69(3):485-494. PubMed ID: 35810485
[TBL] [Abstract][Full Text] [Related]
55. Pain mitigation and management strategies for anti-GD2 infusions: An expert consensus.
Nysom K; Morad AG; Rafael MS; Zier J; Marachelian A; Watt T; Morgenstern DA
Pediatr Blood Cancer; 2023 May; 70(5):e30217. PubMed ID: 36772891
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles.
Tivnan A; Orr WS; Gubala V; Nooney R; Williams DE; McDonagh C; Prenter S; Harvey H; Domingo-Fernández R; Bray IM; Piskareva O; Ng CY; Lode HN; Davidoff AM; Stallings RL
PLoS One; 2012; 7(5):e38129. PubMed ID: 22662276
[TBL] [Abstract][Full Text] [Related]
57. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.
Xu H; Cheng M; Guo H; Chen Y; Huse M; Cheung NK
Cancer Immunol Res; 2015 Mar; 3(3):266-77. PubMed ID: 25542634
[TBL] [Abstract][Full Text] [Related]
58. Recombinant antibodies in the immunotherapy of neuroblastoma: perspectives of new developments.
Bestagno M; Occhino M; Corrias MV; Burrone O; Pistoia V
Cancer Lett; 2003 Jul; 197(1-2):193-8. PubMed ID: 12880981
[TBL] [Abstract][Full Text] [Related]
59. Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen.
Förster-Waldl E; Riemer AB; Dehof AK; Neumann D; Brämswig K; Boltz-Nitulescu G; Pehamberger H; Zielinski CC; Scheiner O; Pollak A; Lode H; Jensen-Jarolim E
Mol Immunol; 2005 Feb; 42(3):319-25. PubMed ID: 15589320
[TBL] [Abstract][Full Text] [Related]
60. GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines.
Durbas M; Horwacik I; Boratyn E; Kamycka E; Rokita H
Int J Oncol; 2015 Sep; 47(3):1143-59. PubMed ID: 26134970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]